



STATE MEDICAID DUR BOARD MEETING
THURSDAY, May 9, 2013
7:00 a.m. to 8:30 a.m.
Cannon Health Building
Room 125



MINUTES

Board Members Present:

Tony Dalpiaz, PharmD.
Mr. Kumar Shah
Kathy Goodfellow, R.Ph.
Cris Cowley, M.D.
Susan Siegfried, M.D.

Mark Balk, PharmD.
Keith Tolman, M.D.
Joseph Miner, M.D.
Kyle Jones, M.D.

Board Members Excused:

George Hamlin, PharmD
Bradford Hare, M.D.

Jay Aldous, DDS

Dept. of Health/Div. of Health Care Financing Staff Present:

Robyn Seely, PharmD.
Lisa V Hunt, R.Ph.
Richard Sorenson, R.N.
Merelynn Berrett, R.N.

Bobbi Hansen, C.Ph.T.
Trevor Smith C.Ph.T.
Heather Santacruz, R.N.
Marisha Kissell, R.N.

Other Individuals Present:

Joanita Lake, UofU
Scott Larson, BMS
Gary Ordera, UofU
Lori Harwarth, Bayer
Charissa Anne, JJ
Jennifer Brinton, MD

Toni Shull, Astellas
Bert Jones, GSK
Aimee Redhair, Astellas
Bryan Larson, UofU
Wayne Roberts, GSK

Meeting conducted by: Tony Dalpiaz, Pharm.D.

1. **Welcome** – Tony Dalpiaz opened the meeting.
2. **Housekeeping** – Robyn Seely reminded guests and board members to sign in.
3. **Board Changes** – Appreciation for Dr Joseph Miner for his service as he is retiring from the board.
4. **P&T Committee report** – Lisa Hunt addressed the board. P&T will look at Xa inhibitors, GLP1 class, and sulfonylurea class. New drug classes to be added for June 2013.
5. **Approval of prior meeting minutes** –
 - a. March DURB meeting minutes were looked at and a motion to approve as written

was given by Mark Balk, Joseph Miner seconded the motion. All approve.

- b. April DURB meeting minutes were looked at with three corrections that were asked to be made. Kathy Goodfellow made a motion approve the April minutes pending the stated changes. Mark Balk seconded the motion. All approve with the exception of those not present at the April meeting, who abstained from the vote.

- 6. **Overactive bladder** – Joanita Lake presented the clinical evidence prepared by the University of Utah Drug Information Center. Myrbetriq (mirabegron) was the only drug that was presented. Recommendation was to recommend mirabegron for patients who have intolerance or have failed on other antimuscularinic drugs.

7. **Public Comment**

- a. Toni Shull (Astellas, Myrbetriq) – Provided information about Myrbetriq including safety and efficacy, trials, and side effects. She asked that Myrbetriq be included in the Medicaid formulary.
- 8. Robyn Seely said that of the four Medicaid ACOs in the state, three of them require prior authorization for Myrbetriq. She also presented the non-preferred drug criteria PA sheet and said that she believed that Myrbetriq is a good candidate for this form.

9. **Board Discussion**

- a. Susan Siegfried asked about if Myrbetriq can cross the blood brain barrier. Toni Shull did not believe that this is the case.
- b. Discussion about the hypertension issues with the drug.
- c. Mark Balk asked if Myrbetriq is on the PDL yet. It is not. He said that his recommendation would be to use this generic PA non preferred drug form unless there are additional safety issues.
- d. Mark Balk made a motion to accept the non-preferred drug authorization form for this drug similar to the other non preferred drug in the OAB class.
- e. Clarification was made that this drug would not be available until trials of the other preferred drugs in the class. Myrbetriq has not been through enough trials to warrant that it is safer than other drugs in the class. It simply has different side effects. The PA would require an valid reason for needing the other agent, not only a trial, but evidence of the need.
- f. Mark Balks motion is seconded by Joseph Miner. All in favor, motion carries.

10. **Meeting adjourned**

The next DUR Board meeting is scheduled for Thursday, June 13, 2013.

Minutes prepared by Trevor Smith.

Recording available upon request, send email to medicaidpharmacy@utah.gov

The Board reviewed 5 petitions